Signal active
Organization
Contact Information
Overview
VISEN is an innovative biopharmaceutical company focused on endocrine diseases. We are dedicated to providing innovative therapies and compassionate, patient-centric care, because we believe that achieving better treatment processes and outcomes results in living better lives. Putting patients’ need first, VISEN is committed to providing first-in-class or best-in-class products and treatments for endocrine diseases. Our therapeutic areas cover endocrine diseases in adults and children, and rare endocrine diseases.
VISEN comprises seasoned professionals with multinational pharmaceutical experiences and leverages cutting-edge technologies and leading resources across the world. We are focused on the Chinese market, and have established offices in Shanghai, Beijing, Hong Kong and Taipei. We have also launched our Greater China R&D and manufacturing site in Suzhou to enhance R&D, manufacturing and commercialization efforts. Our goal is to enable Chinese endocrine patients to benefit from the world's most advanced and reliable treatment solutions earlier.
About
Biotechnology, Life Science, Pharmaceutical
2018
101-250
Headquarters locations
Asia
Social
N/A
Profile Resume
Visen Pharmaceuticals headquartered in Asia, operates in the Biotechnology, Life Science, Pharmaceutical sector. The company focuses on Biotechnology and has secured $4.6B in funding across 24 round(s). With a team of 101-250 employees, Visen Pharmaceuticals is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Visen Pharmaceuticals, raised $40.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
2
3
0
$190.0M
Details
2
Visen Pharmaceuticals has raised a total of $190.0M in funding over 2 rounds.
Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
---|---|---|---|---|
2021 | Early Stage Venture | 150.0M | ||
2018 | Early Stage Venture | 40.0M |
Investors
Visen Pharmaceuticals is funded by 20 investors.
Investor Name | Lead Investor | Funding Round | Partners |
---|---|---|---|
Visen Pharmaceuticals | - | FUNDING ROUND - Visen Pharmaceuticals | 40.0M |
Ascendis Pharma | - | FUNDING ROUND - Ascendis Pharma | 40.0M |
Visen Pharmaceuticals | - | FUNDING ROUND - Visen Pharmaceuticals | 40.0M |
Sofinnova Investments | - | FUNDING ROUND - Sofinnova Investments | 40.0M |
Recent Activity
There is no recent news or activity for this profile.